Creatine Fuels Dendritic Cells to Fight Tumors, New Research Shows

Creatine has spent decades in the shadow of weight rooms and sports nutrition labels, but a new study published in iScience repositions it as a potential player in cancer immunology. Researchers found that dendritic cells, the immune system's sentinels for triggering antitumor T cell responses, actively take up creatine through a dedicated transporter, and that this uptake is essential for their survival, activation, and ability to prime cancer-killing T cells. The work is early and investigational, but the implications for immunotherapy are worth taking seriously.

Creatine Transporter Upregulation in Intratumoral Dendritic Cells

The study, from researchers who analyzed murine conventional dendritic cells (cDCs) isolated directly from tumors, found that the creatine transporter CrT, encoded by the gene SLC6A8, is significantly upregulated when dendritic cells encounter an inflammatory stimulus. This happened both in intratumoral cDCs and in laboratory-cultured bone marrow-derived dendritic cells (BMDCs) stimulated with LPS, a bacterial component that mimics infection. When the team knocked out CrT in BMDCs, the cells showed dramatically reduced survival and failed to fully activate: surface markers like CD25, CD44, and CD69 dropped, proinflammatory cytokines including TNF-a, IL-6, and IL-12 fell, and the cells' capacity to prime antigen-specific T cells collapsed. Creatine, it turns out, is not a passive bystander in immune activation; it is part of the machinery.

The mechanistic explanation runs through energy. CrT-knockout BMDCs had lower intracellular creatine, phosphocreatine, and ATP levels, consistent with impaired operation of the creatine kinase/phosphocreatine/creatine system, which acts as an intracellular ATP buffer. With less available ATP, key transcription factors including NF-kB subunit p65, NFAT, and c-Jun failed to translocate to the nucleus efficiently. The researchers confirmed the ATP link directly: supplementing exogenous ATP to wild-type BMDCs mimicked the activation boost seen with creatine, and treating cells with RGX-202, a creatine transporter inhibitor, suppressed NF-kB signaling by reducing phosphorylation of IKKb, IkBa, and p65.

How Blunted Dendritic Cells Undermine T Cell Antitumor Responses

Dendritic cells sit at a critical checkpoint in cancer immunity. They capture tumor antigens, travel to lymph nodes, and present those antigens to naive T cells, converting them into tumor-specific killers. When that handoff fails, tumors can evade immune surveillance. The CrT-knockout BMDC experiments made this concrete: co-culturing CrT-KO BMDCs with OT1 T cells, which are engineered to respond to a specific antigen, produced T cells that proliferated less, survived at lower rates, and secreted less IL-2 and IFN-g compared to T cells primed by wild-type BMDCs. Adoptive transfer experiments in mice confirmed the same pattern in vivo: losing creatine uptake in the dendritic cell specifically, not in the T cell, was enough to undercut antigen-specific T cell responses.

This points to a gap that existing cancer immunotherapy has not fully addressed. Immune checkpoint blockade (ICB) therapies like anti-PD-1 and anti-CTLA-4 focus on releasing the brakes on T cells, but they rely on competent dendritic cells having already done the priming work. If dendritic cells in the tumor microenvironment are metabolically starved, checkpoint blockade has less to build on. Understanding how tumor microenvironments suppress immune metabolism is an active area of research, and this study suggests creatine availability may be one overlooked lever.

Creatine Supplementation Slows Tumor Growth in a Mouse Melanoma Model

To test whether creatine supplementation could shift the balance in a living tumor, the researchers used B16-OVA melanoma, a standard syngeneic mouse model. Mice given creatine supplementation showed significantly reduced tumor growth compared to controls, and single-cell RNA sequencing of tumor-infiltrating immune cells revealed that creatine treatment enriched inflammatory signaling pathways, including TNF-a production, while increasing the abundance and activation of intratumoral cDC1s specifically. cDC1s are the dendritic cell subset most associated with cross-presenting tumor antigens to CD8+ cytotoxic T cells, so their enrichment is mechanistically meaningful. Transcription factor signatures for IRF8, STAT3, STAT4, and SPI1, all linked to DC maturation and inflammatory identity, were upregulated in creatine-treated cDCs. CD8+ T cells from those tumors also showed enriched pathways related to effector function and activation.

The researchers extended the finding to human cells. Monocyte-derived dendritic cells (MoDCs) cultured from healthy donors and stimulated with TNF-a showed increased CrT gene expression, mirroring the mouse data. Adding creatine to those human MoDCs boosted activation and drove up expression of proinflammatory cytokines including IL1B, IL6, and TNF. In a co-culture system pairing creatine-treated human MoDCs with NY-ESO-1-specific T cells (a cancer-testis antigen model), those T cells showed higher CD25 and CD69 expression and lower CD62L, a pattern consistent with stronger activation and effector differentiation.

Open Questions About Tumor Models, cDC1 Biology, and Long-Term Safety

The study is candid about its boundaries. The in vivo work relied entirely on a single subcutaneous mouse melanoma model, which is a controlled but artificial setting. Orthotopic tumors, patient-derived xenografts, and spontaneous tumor models would provide more physiologically realistic tests of whether creatine supplementation can durably shift DC function across tumor types with different immune infiltration patterns. The researchers also note that the mechanism behind the specific enrichment of cDC1s, rather than other DC subsets, remains unclear. Whether creatine preferentially benefits cDC1 differentiation, survival, or migration into tumors is an open question.

There is also the broader question of creatine's effects on other cells in the tumor microenvironment. Tumor cells, regulatory T cells, and myeloid-derived suppressor cells all compete for metabolites in the TME, and how nutrient availability shapes that competition is not fully resolved. A retrospective analysis of ten years of National Health and Nutrition Examination Survey (NHANES) data, cited in the paper, found that higher dietary creatine intake was associated with a lower incidence of cancer, but population-level associations carry the usual confounders and cannot establish causation.

What Creatine Supplementation Could Mean for Cancer Immunotherapy

The study frames creatine supplementation as a potential co-therapy to increase tumor immunogenicity and overcome resistance to immune checkpoint blockade. Creatine is already known to protect against cancer-associated cachexia and to attenuate doxorubicin-induced cardiotoxicity, meaning it has a plausible safety profile in oncology contexts. Layering dendritic cell-boosting activity on top of that profile is an attractive hypothesis. The compound is inexpensive, orally bioavailable, and well-characterized in humans, which lowers the translational barrier compared to novel biologics.

None of that makes it a proven cancer therapy. The findings are investigational, grounded in mouse models and in vitro human cell work that has yet to be tested in clinical trials. What the study does establish, with reasonable mechanistic rigor, is that creatine uptake through CrT is not optional for dendritic cells trying to do their job in a tumor: it is part of how they sustain the ATP levels needed to activate the signaling cascades that ultimately arm T cells against cancer. That is a precise and testable claim, and it gives the field a clear metabolic target to probe further.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• Primary evidence comes from mouse bone marrow-derived DCs and a single syngeneic subcutaneous tumor model (B16-OVA); human data are limited to in vitro monocyte-derived DC experiments and a retrospective NHANES dietary analysis.
• The retrospective NHANES association between dietary creatine intake and cancer incidence cannot establish causation.
• The study has not been independently replicated, and the mechanism behind creatine-driven cDC1 expansion in tumors remains unresolved.
• Funding source was not disclosed in the available text, so independent verification of the research cannot be confirmed.

This study combines in vitro mouse BMDC experiments, a syngeneic B16-OVA melanoma model, single-cell RNA sequencing, and limited human monocyte-derived DC co-culture data to trace a mechanistic pathway from creatine transporter (SLC6A8) activity to ATP buffering, NF-κB activation, and antitumor DC function. The human evidence is restricted to in vitro assays and a retrospective dietary survey (NHANES), neither of which can establish causation. The findings have not yet been independently replicated in diverse tumor models or prospective human cohorts.